Achromobacter xylosoxidans

Jump to navigation Jump to search
Achromobacter xylosoxidans
Achromobacter xylosoxidans
Achromobacter xylosoxidans
Scientific classification
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Beta Proteobacteria
Order: Burkholderiales
Family: Alcaligenaceae
Genus: Achromobacter
Species: A. xylosoxidans
Binomial name
Achromobacter xylosoxidans
Yabuuchi and Yano 1981[1]
Type strain
ATCC 27061, BCRC 12839, CCM 2741, CCRC 12839, CCTM La 3521, CCUG 12689, CDC KC 1064, CDCKC1064, CECT 467, CECT 927, CGMCC 1.2007, CIP 71.32, DSM 10346, DSM 2402, DSMZ 10346, DSMZ 2402, EY 543, GIFL 543, GIFU 543, Hugh 2838, IAM 12684, IFO 15126, IMD 101001, JCM 9659, KACC 10205, KM 543, LMG 1863, NBRC 15126, NCIB 12033, NCIMB 12033, NCTC 1 O807, NCTC 10807, NRRL 84082, NRRL B-4082, NXRX 10807, PCM 2222, R-16924, R. Hugh 2838, R.Hugh 2838, RH 2838, RIMD 101001, strain KM 543, strain Takeda, VTT E-991282 Yabuuchi KM 543[2]

WikiDoc Resources for Achromobacter xylosoxidans

Articles

Most recent articles on Achromobacter xylosoxidans

Most cited articles on Achromobacter xylosoxidans

Review articles on Achromobacter xylosoxidans

Articles on Achromobacter xylosoxidans in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Achromobacter xylosoxidans

Images of Achromobacter xylosoxidans

Photos of Achromobacter xylosoxidans

Podcasts & MP3s on Achromobacter xylosoxidans

Videos on Achromobacter xylosoxidans

Evidence Based Medicine

Cochrane Collaboration on Achromobacter xylosoxidans

Bandolier on Achromobacter xylosoxidans

TRIP on Achromobacter xylosoxidans

Clinical Trials

Ongoing Trials on Achromobacter xylosoxidans at Clinical Trials.gov

Trial results on Achromobacter xylosoxidans

Clinical Trials on Achromobacter xylosoxidans at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Achromobacter xylosoxidans

NICE Guidance on Achromobacter xylosoxidans

NHS PRODIGY Guidance

FDA on Achromobacter xylosoxidans

CDC on Achromobacter xylosoxidans

Books

Books on Achromobacter xylosoxidans

News

Achromobacter xylosoxidans in the news

Be alerted to news on Achromobacter xylosoxidans

News trends on Achromobacter xylosoxidans

Commentary

Blogs on Achromobacter xylosoxidans

Definitions

Definitions of Achromobacter xylosoxidans

Patient Resources / Community

Patient resources on Achromobacter xylosoxidans

Discussion groups on Achromobacter xylosoxidans

Patient Handouts on Achromobacter xylosoxidans

Directions to Hospitals Treating Achromobacter xylosoxidans

Risk calculators and risk factors for Achromobacter xylosoxidans

Healthcare Provider Resources

Symptoms of Achromobacter xylosoxidans

Causes & Risk Factors for Achromobacter xylosoxidans

Diagnostic studies for Achromobacter xylosoxidans

Treatment of Achromobacter xylosoxidans

Continuing Medical Education (CME)

CME Programs on Achromobacter xylosoxidans

International

Achromobacter xylosoxidans en Espanol

Achromobacter xylosoxidans en Francais

Business

Achromobacter xylosoxidans in the Marketplace

Patents on Achromobacter xylosoxidans

Experimental / Informatics

List of terms related to Achromobacter xylosoxidans

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Overview

Achromobacter xylosoxidans is a Gram-negative, aerobic, oxidase- and catalase-positive, motile bacterium with peritrichous flagella, from the genus Achromobacter found in water environments and was isolated from patients (pulmonary).[3][4] Achromobacter xylosoxidans can cause infections like bacteremia,[5][6] especially for patients who suffer from cystic fibrosis.[7] In 2013, the complete genome of an A. xylosoxidans isolate from CF patient was sequenced.[8]

Treatment

  • Preferred regimen: most active agents are Piperacillin-Tazobactam, Meropenem AND TrimethoprimSulfamethoxazole whereas Ceftazidime is more active than Cefepime
  • Alternative regimen: Colistin inhaled, could also be considered
  • Note : Achromobacter (formerly Alcaligenes) xylosoxidans is a newly emerging microorganism isolated with increased frequency from the lungs of patients with cystic fibrosis. Combination therapy has been recommended for the treatment of Achromobacter xylosoxidans pulmonary exacerbations in cystic fibrosis

References

  1. LPSN bacterio
  2. Strain info of Achromobacter xylosoxidans
  3. Journal of Clinical Microbiology [1]
  4. UniProt
  5. PubMed
  6. Achromobacter xylosoxidans Bacteremia: Report of Four Cases and Review of the Literature, Joan M. Duggan, Steven J. Goldstein, Carol E. Chenoweth, Carol A. Kauffman, and Suzanne F. Bradley [2]
  7. Cystic Fibrosis Medicine
  8. Jakobsen TH, Hansen MA, Jensen PØ, Hansen L, Riber L, et al. (2013) Complete Genome Sequence of the Cystic Fibrosis Pathogen Achromobacter xylosoxidans NH44784-1996 Complies with Important Pathogenic Phenotypes. PLoS ONE 8(7): e68484. doi:10.1371/journal.pone.0068484[http://journals.plos.org/plosone/article? id=10.1371/journal.pone.0068484]
  9. Neuwirth C, Freby C, Ogier-Desserrey A, Perez-Martin S, Houzel A, Péchinot A; et al. (2006). "VEB-1 in Achromobacter xylosoxidans from cystic fibrosis patient, France". Emerg Infect Dis. 12 (11): 1737–9. doi:10.3201/eid1211.060143. PMC 3372329. PMID 17283625.
  10. Sader HS, Jones RN (2005). "Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli". Int J Antimicrob Agents. 25 (2): 95–109. doi:10.1016/j.ijantimicag.2004.10.002. PMID 15664479.
  11. Almuzara M, Limansky A, Ballerini V, Galanternik L, Famiglietti A, Vay C (2010). "In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods". Int J Antimicrob Agents. 35 (1): 68–71. doi:10.1016/j.ijantimicag.2009.08.015. PMID 19889520.
  12. Wang M, Ridderberg W, Hansen CR, Høiby N, Jensen-Fangel S, Olesen HV; et al. (2013). "Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis". J Cyst Fibros. 12 (6): 638–43. doi:10.1016/j.jcf.2013.04.013. PMID 23727271.
  13. Atalay S, Ece G, Samlioğlu P, Kose S, Maras G, Gonullu M (2012). "Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans". Scand J Infect Dis. 44 (10): 798–801. doi:10.3109/00365548.2012.664780. PMID 22404460.
  14. Ciofu O, Hansen CR, Høiby N (2013). "Respiratory bacterial infections in cystic fibrosis". Curr Opin Pulm Med. 19 (3): 251–8. doi:10.1097/MCP.0b013e32835f1afc. PMID 23449384.